Rocket Pharmaceuticals Inc Stock News

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy prog

Upgrades According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from Neutral to Outperform. Diebold Nixdorf earned $1.61 in the first quarter, compared to $0.29 in the

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies

Rocket is running a number of successful rare disease programs. Their data so far is excellent.

Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with understa

During the last session, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)’s traded shares were 0.47 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $15.69, reflecting an intraday loss of -5.77% or -$0.96. The 52-week high for the RCKT share is $58.72, that puts it down … Is Rocket Pharmaceuticals Inc.’s (NASDAQ: RCKT) 6.73% Gain This Week Telling Us Something New? Read More »

Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.69 beats by $0.04.Cash, cash equivalents and investments as of December 31, 2021, were $388.7 million.

Rocket Pharmaceuticals Inc (RCKT) shares closed this week 20.5% higher than it did at the end of last week. The stock is currently down 11.5% year-to-date, down 68.2% over the past 12 months, and up 197.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $20.90 and as low as $15.75 this week.Trading volume this week was 59.7% higher than the 10-day average and 80.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 9.0% The company's stock price performance over the past 12 months lags the peer average by 100.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

From Citizen Kane, chairman of the board Bernstein quips, its no trick to make a lot of money if what you want to do is make a lot of money. Downright laughable was Washington Posts catchy

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET. A live audio webcast of the presentation will be available under Events in the Investors sect

US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades. When insiders purchase shares,

US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades.

The biotech market has seen a massive influx of revenue due to the surging Covid pandemic.